2009 (v1)
Publication
A longitudinal screening for JC polyomavirus (JCV) was performed in natalizumab-treated multiple sclerosis (MS) patients, immunocompromised patients and immunecompetent subjects to identify the incidence of JCV reactivation in these different groups. Thirty-eight MS patients were selected for natalizumab-treatment: 23 patients were treated for...
Uploaded on: March 25, 2023